Performance of Fully Automated Plasma Assays as Screening Tests for Alzheimer Disease-Related β-Amyloid Status.

Palmqvist S, Janelidze S, Stomrud E, Zetterberg H, Karl J, Zink K, Bittner T, Mattsson N, Eichenlaub U, Blennow K, Hansson O. · 2019

Read Performance of Fully Automated Plasma Assays as Screening Tests for Alzheimer Disease-Related β-Amyloid Status. by Palmqvist S, Janelidze S, Stomrud E, Zetterberg H, Karl J, Zink K, Bittner T, Mattsson N, Eichenlaub U, Blennow K, Hansson O. (2019) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc6593637.txt.

Introduction

Palmqvist and co-authors test whether a simple blood test can flag Alzheimer-related amyloid in the brain. Their study appears in JAMA Neurology. Brain amyloid is now found by costly PET scans or spinal fluid tests. A cheap blood screen could widen access a great deal. The team used fully automated plasma assays from Roche. They measured amyloid beta 42, amyloid beta 40, and tau.

The main cohort held 842 people from the Swedish BioFINDER study. A second cohort of 237 people served for validation. The plasma amyloid 42 to 40 ratio predicted brain amyloid status well. It held up across all disease stages in both cohorts. Adding APOE genotype raised the accuracy even further. The authors propose the test for prescreening in primary care and trials.

Catalog record

CREATORPalmqvist S, Janelidze S, Stomrud E, Zetterberg H, Karl J, Zink K, Bittner T, Mattsson N, Eichenlaub U, Blennow K, Hansson O.
YEAR2019
COLLECTIONPAPERS
FORMATTXT
FILE SIZE38 KB
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC6593637

Browse the full library · About the Tower of Babel

Full text

The opening of the work, from the library's hosted text:

Performance of Fully Automated Plasma Assays as Screening Tests for Alzheimer Disease–Related β-Amyloid Status By Sebastian Palmqvist, Shorena Janelidze, Erik Stomrud, Henrik Zetterberg, Johann Karl, Katharina Zink, Tobias Bittner, Niklas Mattsson, Udo Eichenlaub, Kaj Blennow, Oskar Hansson Published in: JAMA Neurology DOI: 10.1001/jamaneurol.2019.1632 ABSTRACT Key Points Question Do plasma levels of β-amyloid 42, β-amyloid 40, and tau detect cerebral β-amyloid status when measured using fully automated immunoassays? Findings In 2 cross-sectional studies, plasma β-amyloid 42 to β-amyloid 40 ratio, measured using immunoassay, accurately predicted cerebral β-amyloid status in all stages of Alzheimer disease in the BioFINDER cohort (n = 842) and in an independent validation cohort (n = 237). The diagnostic accuracy was further increased by analyzing APOE genotype. Meaning Blood-based β-amyloid 42 and β-amyloid 40 ratio together with APOE genotype may be used as prescreening tests in primary care and in clinical Alzheimer disease trials to lower the costs and number of positron emission tomography scans and lumbar punctures. INTRODUCTION A key hallmark of Alzheimer disease (AD) is the gradual accumulation of β-amyloid (Aβ) in the brain, which starts decades before the onset of cognitive symptoms. Detection of abnormal Aβ accumulation (Aβ positivity) may support the clinical diagnosis of AD1,2 and is essential for including participants in clinical AD trials targeting Aβ.3 β-Amyloid can be detected in vivo using positron emission tomography (PET) with ligands that bind to Aβ fibrils or by measuring the levels of the peptide Aβ1-42 (Aβ42) in cerebrospinal fluid (CSF).4 Alzheimer disease affects 1 in 10 persons aged 65 years and older and is expected to affect more than 100 million people by 2050.5,6 The costs and limited access to PET or CSF analysis may restrict their use to a minority of cases. There is thus a great need for readily available methods that can detect brain Aβ, and perhaps the most desirable goal has been to establish blood-based biomarkers of Aβ. Many candidate blood biomarkers have failed in replication studies,7,8 but somewhat promising results have been seen for plasma tau, neurofilament light chain (NFL), and combinations of Aβ42 and Aβ40.9,10,11,12,13,14,15,16,17 Although there are diagnostic inconsistencies regarding the plasma Aβ42/Aβ40 ratio in older studies,18 more recent studies have demonstrated that it correlates with brain Aβ and can differentiate patients with AD from healthy control participants.12,13 Most recently, 2 independent groups demonstrated improved accuracy for plasma Aβ42/Aβ40 using immunoprecipitation–mass spectrometry assays.19,20 Although these studies are promising and show the potential of plasma Aβ as a true AD biomarker, they are costly and need extensive development before they can be implemented in primary care or in large screenings where cost-effective, fully automated, high-throughput, and highly reliable analysis methods are needed. Measuring plasma Aβ presents the same challenges as measuring CSF Aβ in that several analysis methods exist and unified cutoffs have been difficult to establish, even using the same assay, owing to high variability between laboratories and assay batches.21,22 Recently, fully automated immunoassays have been developed by several different vendors with improved reliability and precision for CSF Aβ and tau species.23,24,25 For example, for the Elecsys immunoassays (Roche Diagnostics), it has been shown that CSF cutoffs established in one European cohort could be applied to another independent cohort in the United States to determine amyloid PET status with high accuracy.24 Using these newly developed Elecsys assays for detection of Aβ42, Aβ40, and tau, our aims were to examine the accuracy of plasma Aβ42, Aβ40, and tau to estimate Aβ positivity, whether the accuracy could be improved by adding plasma neurofilament (light and heavy chain) and APOE genotype to the models, and how the Elecsys assays perform in an independent validation cohort. METHODS Participants The study population was included from the prospective Swedish BioFINDER Study, which enrolled participants between July 6, 2009, to February 11, 2015, from the southern part of Sweden. Of all 892 participants in BioFINDER’s control, mild cognitive symptoms, and AD cohorts, plasma samples were hemolyzed or not available in sufficient amount for 50 individuals. Thus, 842 participants could be included in the present study. They were classified as cognitively unimpaired26 (CU; 513 participants, of whom 195 had subjective cognitive decline)27; mild cognitive impairment28 (MCI; 265 participants); or AD dementia2 (64 participants). In subsample analyses, we grouped the population into CU and cognitively impaired (MCI + AD), because all participants with AD were Aβ positive and therefore could not be examined separately using Aβ status as outcome. Study design and specific inclusion and exclusion criteria are described elsewhere29 (eMethods in the Supplement). The study was approved by the Regional Ethics Committee in Lund, Sweden, and all participants gave their written informed consent to participate in the study. For the independent validation cohort, the study was approved by the ethical committee of the Medizinische Hochschule in Hannover and the ethical committee of the University of Ulm, and all participants gave written informed consent. Plasma and CSF Procedures Blood samples were collected at the same time as CSF samples, and the collection was performed in the morning with participants not fasting. Blood samples were collected and analyzed according to a standardized protocol. For each study participant, blood was collected in 6 EDTA-plasma tubes (Vacutainer K2EDTA tube; BD Diagnostics) and centrifuged (2000 g, 4°C) for 10 minutes. After centrifugation, plasma from all 6 tubes was transferred into one 50-mL tube (62.547.254, Sarstedt), mixed, and 1 mL was aliquoted into polypropylene tubes (72.694.100; Sarstedt) and stored at –80°C within 30 to 60 minutes of collection. All plasma samples went through 1 freeze-thaw cycle before the analysis, when 300 μL was further aliquoted into Lobind tubes (72.704.600; Sarstedt). The current standardized protocol is consistent with recent findings that blood must be centrifuged within 1 hour and frozen shortly thereafter; however, up to 3 freeze-thaw cycles and 5 tube transfers do not affect plasma Aβ and tau values.30 Lumbar puncture and CSF handling followed a structured protocol.31 Plasma and CSF Aβ42, Aβ40, total tau (tau), and phosphorylated tau (P-tau; only in CSF) were analyzed using the Elecsys immunoassays on a cobas e 601 analyzer (Roche Diagnostics) at the Clinical Neurochemistry Laboratory, University of Gothenburg, Sweden. Additional assay data (also including NFL and neurofilament heavy chain [NFH] analyses) can be found in the eMethods and eTables 1 and 2 in the Supplement. Reference Standard for Aβ Status β-Amyloid status was determined using the Elecsys CSF Aβ42/Aβ40 ratio, which is a ratio that has been validated against amyloid PET status with more than 90% agreement.32,33,34 An unbiased cutoff of less than 0.059 was used to define Aβ positivity based on mixture modeling statistics, which previously has proved to provide robust and accurate thresholds.35,36 In a secondary analysis (eFigure 3 and eFigure 4 in the Supplement), we used the Elecsys CSF P-tau/Aβ42 ratio to define Aβ positivity, using the predefined cutoff of 0.022 or greater.24 Independent Validation Cohort All 237 participants of this study were enrolled between January 29, 2000, and October 11, 2006, at 2 clinical sites in Germany, Ulm and Hannover, as part of a prospective validation study of new biomarkers for the early diagnosis of AD. The participants were classified as having CU (n = 34), MCI (n = 109),37 or AD mild dementia38 (Mini-Mental State Examination score >22; n =

Read the complete text